






































Rilpivirine vs. efavirenz-based single-tablet regimens
in treatment-naive adults: week 96 efficacy and safety
from a randomized phase 3b study
Jan van Lunzena, Andrea Antinorib, Calvin J. Cohenc, José R. Arribasd,
David A. Wohle, Armin Riegerf, Anita Rachlisg, Mark Blochh,
Sorana Segal-Maureri, Will Garnerc, Danielle Porterc, Matthew Bossec,
David Piontkowskyc, Susan K. Chuckc and Shampa De-Oertelc
Objectives: To compare efficacy, safety, tolerability, and patient-reported outcomes 
between two single-tablet regimens, rilpivirine/emtricitabine/tenofovir disoproxil 
fumarate (RPV/FTC/TDF) and efavirenz/emtricitabine/tenofovir disoproxil fumarate 
(EFV/FTC/TDF), in HIV-1-infected, treatment-naive adults.
Design: This was a phase 3b, 96-week, randomized, open-label, international, non-
inferiority trial.
Methods: A total of 799 participants were randomized (1 : 1) to receive RPV/FTC/TDF 
or EFV/FTC/TDF. The primary efficacy endpoint evaluated proportions of participants 
with HIV-1 RNA less than 50 copies/ml using the Snapshot algorithm. Additional 
assessments included CD4þ cell counts, genotypic/phenotypic resistance, adverse 
events, patient-reported outcomes, and quality of life questionnaires.
Results: At week 96, trial completion rates were 80.2% (316/394; RPV/FTC/TDF) and 
74.0% (290/392; EFV/FTC/TDF). Overall, RPV/FTC/TDF was noninferior to EFV/FTC/
TDF [HIV-1 RNA <50 copies/ml: 77.9 vs. 72.4%, respectively; difference –5.5; 95%CI 
(–0.6, 11.5); P ¼ 0.076]. RPV/FTC/TDF was significantly more efficacious compared 
with EFV/FTC/TDF in participants with baseline HIV-1 RNA equal to or less than 
100 000 copies/ml (78.8 vs. 71.2%; P ¼ 0.046) and in those with CD4þ cell count 
greater than 200 cells/ml (80.6 vs. 73.0%; P ¼ 0.018). There was no significant between-
group difference in the CD4þ cell count increase (278  189 vs. 259  191 cells/ml; 
P ¼ 0.17). Few participants developed resistance after week 48 (1.0% RPV/FTC/TDF; 
0.3% EFV/FTC/TDF). Compared with EFV/FTC/TDF, RPV/FTC/TDF was associated with 
fewer adverse event-related discontinuations (3.0 vs. 11.0%; P<0.001), significantly 
fewer adverse events due to central nervous system issues and rash, greater improve-
ments in patient-reported symptoms, and significant improvements in the SF-12v2 
quality of life questionnaire mental health composite score (P ¼ 0.014).
Conclusion: In treatment-naive, HIV-1-infected participants, 96-week RPV/FTC/TDF 
treatment demonstrated noninferior efficacy and better tolerability than EFV/FTC/TDF. 
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Introduction
In HIV-1-positive individuals, antiretroviral treatment
with single-tablet regimens (STRs) has been shown to
improve virologic suppression, treatment adherence,
quality of life (QoL), and treatment satisfaction, and to
reduce the rate of virologic failure, compared with
multi-tablet regimens [1–3]. In 2011, the once-daily
STR comprising 25 mg rilpivirine (RPV), 200 mg
emtricitabine (FTC), and 300 mg tenofovir disoproxil
fumarate (TDF; RPV/FTC/TDF; Complera in United
States, Eviplera in European Union) was approved to
treat HIV-1 infections in treatment-naive adults in
the United States and European Union [4,5]. In 2013,
the indication was expanded to include virologically
suppressed patients without resistance to regimen
components who wish to replace their current,
stable regimen. For treatment-naive patients, RPV/
FTC/TDF is indicated for those with HIV-1 RNA load
equal to or less than 100 000 copies/ml at therapy
initiation.
Initial approval of RPV/FTC/TDF was based on two
double-blind, double-dummy studies (ECHO and
THRIVE) that demonstrated noninferior efficacy,
improved tolerability, and fewer adverse event-related
discontinuations following treatment with RPV vs.
efavirenz (EFV) when administered in combination with
two nucleoside or nucleotide reverse transcriptase
inhibitors (N[t]RTIs) [6–9].
The single-tablet regimen trial (STaR) was a 96-week,
open-label study designed to directly compare the
safety and efficacy of the two STRs, RPV/FTC/TDF
and co-formulated EFV, emtricitabine (FTC), and
tenofovir disoproxil fumarate (EFV/FTC/TDF;
Atripla) in HIV-1-infected treatment-naive adults. At
the week 48 primary endpoint, RPV/FTC/TDF
demonstrated noninferior efficacy and a low rate
of resistance development in individuals with less
than 100 000 copies/ml [10]. Additionally, RPV/FTC/
TDF showed better tolerability [11] and was associated
with fewer patient-reported neuropsychiatric and
gastrointestinal symptoms compared with EFV/
FTC/TDF (Gilead data on file; manuscript in
preparation). Thus, this STR may be a suitable
long-term therapy for treatment-naive, HIV-positive
participants.
In this manuscript, we report the efficacy, safety,
resistance, and patient-reported outcomes (PROs) from
the STaR trial collected through week 96.
Methods
Study design and procedures
Design of this study has been reported in more detail
previously [11]. In brief, this phase 3b, 96-week,
international, open-label study (GS-US-264-0110,
NCT01309243, EUDRACT 2010-024007-27) com-
pared the safety and efficacy of once-daily single-tablet
regimens of coformulated 25 mg RPV, 200 mg FTC, and
300 mg TDF (taken with a meal) and coformulated
600 mg EFV, 200 mg FTC, and 300 mg TDF (taken on an
empty stomach, preferably at bedtime) in HIV-1-
infected, antiretroviral treatment-naive adults (HIV-1
RNA 2500 copies/ml) without resistance to any study
drug component and who lacked the RPV mutations
K101E/P, E138A/G/K/Q/R, Y181C/I/V, and H221Y.
The participants were randomized by HIV-1 RNA level
strata at screening (100 000 and >100 000 copies/ml).
HIV-1 RNA levels were assessed using COBAS
AMPLICOR Monitor Version 1.5 (Roche Diagnostics,
Basel, Switzerland).
Efficacy parameters
The primary efficacy endpoint was the proportion of
participants with HIV-1 RNA less than 50 copies/ml
determined using Snapshot analysis [12] at week 48.
Secondary objectives included efficacy using Snapshot
and changes from baseline in CD4þ cell count at week 96.
Additional analyses included efficacy stratified by HIV-1
RNA (100 000 or >100 000 copies/ml) or CD4þ cell
count (200 or >200 cells/ml) at screening and efficacy
by time to loss of virologic response (TLOVR) analysis
[13] with baseline HIV-1 RNA levels included in the
model (100 000 copies/ml vs. >100 000 copies/ml).
Patient reported outcomes (PROs) included the HIV
symptom index questionnaire (HIV SIQ) [14], the HIV
treatment satisfaction questionnaire (HIVTSQ) [15,16],
and a QoL assessment, performed by means of SF-12v2
[17]. Treatment adherence was assessed by means of pill
count and by participant self-report, assessed through an
abbreviated version of the medication adherence self-
report inventory with visual analogue scale [18].
Drug resistance
At screening, protease/reverse transcriptase genotyping
was performed using the GeneSeq assay (Monogram
Biosciences, South San Francisco, California, USA). The
postbaseline resistance analysis population (RAP)
included isolates from individuals with HIV-1 RNA at
least 400 copies/ml and either suboptimal virologic
response (less than 1 log10 decrease in HIV-1 RNA
from baseline at week 8 confirmed at the subsequent visit)
or confirmed virologic rebound (HIV-1 RNA 50
copies/ml at two consecutive visits after reaching HIV-1
RNA <50 copies/ml or 1 log10 increase in HIV-1
RNA from nadir at two consecutive visits). Isolates from
individuals who were on study drugs, had not been
analyzed previously, and had HIV-1 RNA at least
400 copies/ml at weeks 48 or 96 or their last study visit
were also analyzed for resistance development. Postbase-
line genotypic and phenotypic testing was done for
protease transcriptase and reverse transcriptase using the
PhenoSense GT assay (Monogram Biosciences).
Safety evaluation
Data on treatment-emergent adverse events (TEAEs) and
laboratory findings were collected up to 30 days after the
last dose of study drug. Specific TEAEs of importance
were based on adverse effects described in at least one
label for a RPV- or EFV-containing product, focusing on
nervous system disorders, psychiatric disorders, and rash
(Supplemental Table 1, http://links.lww.com/QAD/
A794). Creatinine clearance (Cockcroft-Gault formula
using observed body weight) and the level of lipids in
plasma (triglycerides and the total; HDL, high-density
lipoprotein; and LDL, low-density lipoprotein choles-
terol – collected in the fasted state) were also monitored.
Statistical analysis
Efficacy and safety analyses were similar to those used in
the week 48 analysis [11] and included participants who
were randomized and received at least one dose of study
medication (Full Analysis Set and Safety Populations,
respectively). The proportions of participants with
virologic success and failure were analyzed using a
Cochran–Mantel–Haenszel test, stratified by baseline
HIV-1 RNA levels (100 000 vs. >100 000 copies/ml).
For assessments based on the Snapshot algorithm, RPV/
FTC/TDF was considered noninferior to EFV/FTC/
TDF if the lower bound of the 95% confidence interval
(CI) of the between-treatment difference (RPV/FTC/
TDF–EFV/FTC/TDF) was greater than –12%. If
noninferiority was demonstrated, and if the lower bound
of the 95% CI of the between-treatment difference was
more than 0 (consistent with P<0.05 at a¼0.05, two-
sided), then RPV/FTC/TDF was deemed superior to
EFV/FTC/TDF. Changes from baseline in CD4þ cell
counts were compared using an analysis of variance
(ANOVA), with treatment and baseline HIV-1 RNA
levels (100 000 or >100 000 copies/ml) as fixed effects.
In this manuscript, with the exception of the HIV
snapshot results, missing data were excluded from the
analyses. Between-treatment comparisons for incidence
of TEAEs of importance were performed using the
Fisher’s exact test. Changes from baseline in fasting lipid
parameters were analyzed with ANOVA, with treatment
as a fixed effect in the model. HIV SIQ changes from
baseline and between-treatment differences were eval-
uated using the McNemar test and the Cochran–
Mantel–Haenszel test with modified ridit scores,
respectively; changes from baseline and between-treat-
ment differences for SF-12v2 were compared using the
Wilcoxon signed-rank test and the x2-square test,
respectively. For HIVTSQ, total treatment satisfaction
scores were compared using an ANOVA with treatment
as a fixed effect.
Results
Baseline characteristics
Of the 799 randomized participants, 786 received at
least one dose of study drug (the Full Analysis Set
and Safety Population were the same). Week 96
completion rates were 80.2% (316/394; RPV/FTC/
TDF) and 74.0% (290/392; EFV/FTC/TDF). Baseline
Table 1. Virologic outcomes at week 96, Snapshot analysis (Full Analysis Set), n (%).
RPV/FTC/TDF,N¼394 EFV/FTC/TDF,N¼392
Virologic success
(HIV-1 RNA <50 copies/ml) 307 (77.9) 284 (72.4)
Difference (95%CI) 5.5 (–0.6,11.5)
P-value 0.076
Virologic failure 37 (9.4) 23 (5.9)
Difference (95%CI) 3.7 (–0.1,7.4)
P-value 0.052
HIV-1 RNA 50 copies/ml 6 (1.5) 6 (1.5)
Treatment discontinuation due to lack of efficacy 16 (4.1) 4 (1.0)
Treatment discontinuation due to other reasonsa and last
available HIV-1 RNA 50 copies/ml
15 (3.8) 13 (3.3)
No data in the study window 50 (12.7) 85 (21.7)
Treatment discontinuation due to adverse event or death 12 (3.0) 42 (10.7)
Treatment discontinuation due to other reasonsy and last
available HIV-1 RNA <50 copies/ml
31 (7.9) 37 (9.4)
Missing data during study window while receiving study drug 7 (1.8) 6 (1.5)
P-values refer to the superiority comparisons (Cochran–Mantel–Haenszel test), conducted because between-treatment differences fulfilled the
noninferiority criterion of the lower bound of the 95% CI being greater than –12%. CI, confidence interval; EFV/FTC/TDF, efavirenz/emtricitabine/
tenofovir disoproxil fumarate; RPV/FTC/TDF, rilpivirine/emtricitabine/tenofovir disoproxil fumarate.
aOther reasons may include loss to follow-up, consent withdrawal, nonadherence, protocol violation and other reasons.
demographic and clinical characteristics, reported pre-
viously, were similar between the two groups [12]. Briefly,
the overall mean SD (standard deviation) age was
37 11 years, and the study population predominantly
consisted of male [92.9% (730/786)] and white participants
[67.2% (528/786)]. The mean SD HIV-1 RNA was
4.8 0.6 log10 copies/ml. A total of 510 (64.9%)
participants had HIV-1 RNA or less than
100 000 copies/ml, 215 (27.4%) had more than 100 000
and/or less than 500 000 copies/ml, and 61 (7.8%) had
more than 500 000 copies/ml. The overall mean SD
CD4þ cell count was 391 183 cells/ml.
Efficacy
At week 96, trial completion rates were 80.2% (316/394;
RPV/FTC/TDF) and 74.0% (290/392; EFV/FTC/
TDF) and RPV/FTC/TDF was noninferior to EFV/
FTC/TDF [difference 5.5%, 95% (CI –0.6 to 11.5%);
superiority test P-value: 0.076; Table 1]. For comparison,
those rates at week 48 were 85.8 and 81.6%, respectively
[difference 4.1%, 95% CI (–1.1 to 9.2%); superiority test
P-value: 0.12] [11].
Overall virologic failure rates via Snapshot analysis at
week 96 (9.4 vs. 5.9%: Table 1) were similar to those
observed at week 48 [RPV/FTC/TDF: 8.1% (32/394);
EFV/FTC/TDF: 5.1% (20/392); difference 3.2%, 95%
(CI –0.3 to 6.7%); superiority test P-value: 0.071].
Participants in the RPV/FTC/TDF group that had HIV-
1 RNA less than 100 000 copies/ml demonstrated a
significant difference in virologic success vs. EFV/FTC/
TDF (78.8 vs. 71.2%, superiority test P-value: 0.046;
Table 2). In addition, an analysis based on the baseline
CD4þ cell count strata (equal to or less than 200 cells/ml
vs. >200 cells/ml) showed significant differences in
virologic success in those with more than 200 cells/ml
[80.6% (RPV/FTC/TDV) vs. 73.0% (EFV/FTC/TDF),
superiority test P-value: 0.018; Table 2]. Discontinuation
rates due to lack of efficacy were 4.1% (16/394) and
1.0% (4/392), respectively. Of the 16 study participants
in the RPV/FTC/TDF arm who discontinued due
to lack of efficacy, five had baseline HIV-1 RNA
greater than 100 000–500 000 copies/ml and eight had
baseline HIV-1 RNA greater than 500 000 copies/ml. In
the EFV/FTC/TDF, of the four participants who
discontinued due to lack of efficacy, three had baseline
HIV-1 RNA equal to or less than 100 000 copies/ml
and one had baseline HIV-1 RNA greater than
500 000 copies/ml. Adherence was similar between the
two groups as assessed via pill count (RPV/FTC/TDF,
96.8%; EFV/FTC/TDF, 96.4%) or M-MASRI (44% in
each group reported never missing a dose when asked
at week 96).
Visit-by-visit data suggests a maximal rate of virologic
success after 24 weeks of treatment in both groups
Table 2. Participants achieving HIV-1 RNA less than 50 copies/ml by baseline HIV-1 RNA at week 96 by Snapshot analysis, stratified by HIV-1
RNA and CD4R cell count (Full Analysis Set), n (%).
HIV-1 RNA <50 copies/ml
Stratification RPV/FTC/TDF (N¼394) EFV/FTC/TDF (n¼392)
By baseline HIV-1 RNA copies/ml
100 000, n 260 250
n, % 205 (78.8) 178 (71.2)
Difference (95%CI) 7.6 (0.2, 15.1)
P-value 0.046
>100 000, n 134 142
n, % 102 (76.1) 106 (74.6)
Difference (95%CI) 1.5 (–8.7,11.6)
P-value 0.78
>100 000 to 500 000, n 98 117
n, % 80 (81.6) 88 (75.2)
Difference (95%CI) 6.4 (–4.5, 17.4)
P-value 0.26
>500 000, n 36 25
n, % 22 (61.1) 18 (72.0)
Difference (95%CI) –10.9 (–34.6, 12.8)
P-value 0.38
By baseline CD4þ cell count (cells/ml)
200, n 53 51
n, % 32 (60.4) 35 (68.6)
Difference (95%CI) –8.0 (–26.7,10.7)
P-value 0.40
>200, n 341 341
n, % 275 (80.6) 249 (73.0)
Difference (95%CI) 7.7 (1.3,14.0)
P-value 0.018
P-values refer to the superiority comparisons (Cochran–Mantel–Haenszel test), conducted because between-treatment differences fulfilled the
noninferiority criterion of the lower bound of the 95% CI being greater than –12%. CI, confidence interval; EFV/FTC/TDF, efavirenz/emtricitabine/
tenofovir disoproxil fumarate; RPV/FTC/TDF, rilpivirine/emtricitabine/tenofovir disoproxil fumarate.
(>85%), with a slow decline over the subsequent
72 weeks and no between-group differences (Fig. 1).
The Snapshot analysis of virologic failure demonstrated a
significant difference between treatment groups in
participants who had HIV-1 RNA greater than
500 000 copies/ml [RPV/FTC/TDF: 33.3% (12/36);
EFV/FTC/TDF: 8.0% (2/25); difference 25.3%, 95% CI
(6.6–44.0%); superiority test P-value: 0.022] and those
with CD4þ cell count or less than 200 cells/ml [RPV/
FTC/TDF: 30.2% (16/53); EFV/FTC/TDF: 9.8%
(5/51); difference 20.5%, 95% CI (5.136.0%); superiority
test P-value: 0.010].
The TLOVR analysis demonstrated that the RPV/FTC/
TDF group had a significantly higher proportion of
participants who achieved and maintained virologic
success through week 96 than the EFV/FTC/TDF group
[79.4 vs. 73.0%; difference 6.6%, 95% CI (0.7–12.6%;
P¼ 0.030]. In both groups, the mean CD4þ cell counts
increased markedly from baseline to week 96 (RPV/
FTC/TDF: 278 189 cells/ml; EFV/FTC/TDF:
259 191 cells/ml), but without a significant between-
group difference (P¼ 0.17). This outcome is similar to
the one observed at week 48, where an increase in CD4þ
cell count in both groups was also observed (RPV/
FTC/TDF, 200 159 cells/ml; EFV/FTC/TDF,
191 144 cells/ml; P¼ 0.34).
Resistance development
As reported in more detail previously [19], the RAP
through week 96 included 24 of 394 participants (6.1%)
receiving RPV/FTC/TDF and nine of 392 participants
(2.3%) receiving EFV/FTC/TDF (see Supplemental
Table 3, http://links.lww.com/QAD/A794). In the
RPV/FTC/TDF arm, 21 of 394 participants (5.3%;
88% of RAP) developed non-nucleoside reverse-trans-
criptase inhibitors (NNRTI) and/or NRTI resistance
mutations and 20 of 21 isolates had both NNRTI and
NRTI genotypic and/or phenotypic resistance. In the
EFV/FTC/TDF arm, isolates from four of 392
participants (1.0%; 44% of RAP) developed NNRTI
and/or NRTI resistance mutations. Few participants
developed resistance after week 48 (1.0% RPV/FTC/
TDF; 0.3% EFV/FTC/TDF). When stratified by base-
line HIV-1 RNA equal to or less than or greater than
100 000 copies/ml, nine of 260 (3.5%) vs. 12 of 134
(9.0%) RPV/FTC/TDF-treated participants and 3 of 250
(1.2%) vs. one of 142 (0.7%) EFV/FTC/TDF-treated
participants developed resistant isolates, respectively.
Safety and tolerability
The two treatment groups had similar proportions of
participants with at least one TEAE (RPV/FTC/TDF,
91.9%; EFV/FTC/TDF, 93.9%) or at least one treat-
ment-emergent severe adverse event (TESAE; 9.1 vs.
12.2%). Through week 96, 10.2% of RPV/FTC/TDF-
treated and 16.6% of EFV/FTC/TDF-treated partici-
pants experienced a grade 3–4 TEAE, with 0.8 and 2.0%
participants, respectively, reporting a life-threatening
(grade 4) event and 2.3 and 5.6% experiencing a grade
3–4 TEAE deemed related to study drug. For TEAEs of
importance, the rates of nervous system disorders,
psychiatric disorders, and rash events were each
significantly lower in the RPV/FTC/TDF group,
compared with the EFV/FTC/TDF group (Table 3).
See Supplemental Table 2, http://links.lww.com/QAD/
A794, for the list of most frequently reported TEAEs by
system organ class and preferred term.



































RPV/FTC/TDF (n = 394)
EFV/FTC/TDF (n = 392)
Study week 
Fig. 1. Virologic successM by visit (missing data equals fail-
ure, Full Analysis Set). Virologic success was defined as
HIV-1 RNA less than 50 copies/ml. EFV/FTC/TDF, efavirenz/
emtricitabine/tenofovir disoproxil fumarate; RPV/FTC/TDF,
rilpivirine/emtricitabine/tenofovir disoproxil fumarate.
Table 3. Most frequently reported TEAEs of importancea (any grade,
>5% of participants in either group, safety population), n (%).
System organ class RPV/FTC/TDF EFV/FTC/TDF P-value
Preferred term N¼394 N¼392
Nervous system events 107 (27.2) 186 (47.4) <0.001b
Dizziness 27 (6.9) 90 (23.0)
Headache 56 (14.2) 62 (15.8)
Somnolence 10 (2.5) 30 (7.7)
Psychiatric events 111 (28.2) 192 (49.0) <0.001b
Abnormal dreams 23 (5.8) 101 (25.8)
Anxiety 28 (7.1) 37 (9.4)
Depression 36 (9.1) 47 (12.0)
Insomnia 45 (11.4) 59 (15.1)
Rash events 62 (15.7) 95 (24.2) 0.003b
Rashc 31 (7.9) 52 (13.3)
EFV/FTC/TDF indicates efavirenz/emtricitabine/tenofovir disoproxil
fumarate; RPV/FTC/TDF, rilpivirine/emtricitabine/tenofovir diso-
proxil fumarate; TEAE, treatment-emergent adverse event. aFull list
of items is provided in Supplemental Table 1, http://links.lww.com/
QAD/A794.
bStatistical comparison refers to prespecified TEAE subsets within
each system organ class.
cPreferred term rash was used when a more specific type of rash was
not indicated by the investigator.
Through week 96, significantly fewer participants
receiving RPV/FTC/TDF (3.0%) permanently discon-
tinued study drug due to a TEAE, compared with EFV/
FTC/TDF (11.0%; P< 0.001). In the EFV/FTC/TDF
group, the most frequent TEAE leading to discontinu-
ation was a psychiatric event; in the RPV/FTC/TDF
group, no single TEAE led to permanent discontinuation
in more than one participant (Table 4). In both groups,
permanent study drug discontinuations were more
frequent during weeks 5–48 than before or after that
period (Table 4). All discontinuations due to skin and
subcutaneous tissue disorders (i.e. rash) were recorded
during the first 4 weeks of treatment, all occurring in the
EFV/FTC/TDF group (Table 4).
Two participants died during the study (one due to
suicide, one due to septic shock), both in the EFV/FTC/
TDF group; neither death was deemed related to study
drug. By week 96, grade 3 treatment-emergent
laboratory anomalies (TELAs) were experienced by
13.2 and 12.9% of RPV/FTC/TDF- and EFV/FTC/
TDF-treated participants, respectively; rates of grade 4
TELAs were 8.7 and 7.2%. Fewer than 5% of participants
in either group experienced a grade 3 or grade 4 TELA
for any individual parameter, except for creatine kinase
(RPV/FTC/TDF: 6.9%; EFV/FTC/TDF: 7.5%).
The median changes from baseline to week 96 in
creatinine clearance were –5.2 ml/min in the RPV/
FTC/TDF group and þ4.3 ml/min in the EFV/FTC/
TDF group. Three individuals, all of whom were black,
permanently discontinued study drug due to renal
disorders: two of them, one in each study arm,
discontinued during the first 48 weeks due to renal
failure, which resolved after stopping the treatment
(further details in Cohen et al. [11]); the third, in the
EFV/FTC/TDF group, discontinued treatment during
week 74 due to proteinuria and hypoproteinemia (see
Supplemental Data for details, http://links.lww.com/
QAD/A794). At week 96, proteinuria was observed
in 1.5 and 3.0% RPV/FTC/TDF- and EFV/FTC/
TDF-treated participants, respectively. Laboratory results
did not reveal patterns that would indicate proximal renal
tubulopathy in either group.
At week 96, compared with the RPV/FTC/TDF group,
the EFV/FTC/TDF group had a significantly greater
increase in mean SD total cholesterol (25 32 mg/dl
EFV/FTC/TDF vs. 3 33 mg/dl RPV/FTC/TDF;
P< 0.001), LDL cholesterol (15 28 vs. 2 27 mg/dl;
P< 0.001), and HDL cholesterol (9 11 vs. 2 10 mg/
dl; P< 0.001). Changes in triglyceride levels were not
significantly different between the groups (8 111 mg/dl
RPV/FTC/TDF vs. –5 69 mg/dl EFV/FTC/TDF;
P¼ 0.090). The mean SD change in total/HDL
cholesterol ratio in both groups was –0.2 1.1.
At week 96, participants in the RPV/FTC/TDF group
reported a significant reduction in occurrence of 18 out of
20 HIV SIQ symptoms vs. baseline (P  0.039), and
participants in the EFV/FTC/TDF group reported a
significant reduction in seven out of 20 symptoms
(P0.033; see Supplemental Figure 1, http://links.lww.
com/QAD/A794). Significant between-group differ-
ences in the distribution of symptom occurrence vs.
baseline (no change, gain, or loss) were found for eight
symptoms (fatigue; sleep difficulties; feeling sad or
depressed; problems with having sex; pain, numbness
or tingling in hands or feet; hair loss or changes; fevers,
chills, or sweats; cough or trouble catching breath), all
favoring RPV/FTC/TDF (see Supplemental Figure 1,
http://links.lww.com/QAD/A794).
Overall satisfaction with treatment at week 96 was high in
both groups, as indicated by mean HIVTSQ scores at
least 57. For all eight subdomains of the SF-12v2, a QoL
measure, mean scores at week 96 were similar between
treatment groups (data not shown). The between-group
difference in the median change from baseline at week
96 for the physical health composite score was not
significant [0.3 (RPV/FTC/TDF) vs. 1.0 (EFV/FTC/
TDF); P¼ 0.062], but the difference for the mental
health composite score was, favoring RPV/FTC/TDF
(2.4 vs. 0.0; P¼ 0.014).
Table 4. Most frequently reported TEAEs leading to permanent study drug discontinuation by system organ class and time of discontinuationa
(Safety Population), n (%).
RPV/FTC/TDF (N¼394) EFV/FTC/TDF (N¼392)
Weeks Weeks
System organ class 1–4 5–48 49–96 Total 1–4 5–48 49–96 Total
Psychiatric disorders 0 1 0 1 (0.3) 5 11 8 24 (6.1)
Nervous system disorders 0 2 1 3 (0.8) 5 2 1 8 (2.0)
Skin and subcutaneous tissue disorders (e.g. rash) 0 0 0 0 7 0 0 7 (1.8)
Clinical laboratory investigations 0 2 2 4 (1.0) 0 2 0 2 (0.5)
General disorders (e.g. fatigue) 0 0 0 0 3 1 1 5 (1.3)
Gastrointestinal disorders 0 1 0 1 (0.3) 1 2 0 3 (0.8)
EFV/FTC/TDF, efavirenz/emtricitabine/tenofovir disoproxil fumarate; RPV/FTC/TDF, rilpivirine/emtricitabine/tenofovir disoproxil fumarate; TEAE,
treatment-emergent adverse event. aPermanent study drug discontinuation could be due to greater than 1 TEAE; system organ classes with at least
four TEAEs overall are listed.
Discussion
Results of this trial indicate that in treatment-naive, HIV-
1-infected participants, 96-week RPV/FTC/TDF treat-
ment demonstrated noninferior efficacy and better
tolerability than EFV/FTC/TDF. Week 96 data for the
overall study population from this open-label study are in
agreement with previously reported findings at week 48
[11] and with earlier double-blind studies [6–9].
The rate of virologic success at week 96 observed for
RPV/FTC/TDF (78%) was nominally greater than that
observed for RPV-containing regimens in the ECHO
and THRIVE trials (76%) [7], whereas the rate observed
for EFV/FTC/TDF (72%) was nominally lower than that
of the EFV-containing regimens in the double-blind
studies (77%) [7]. These nominal, relatively small
differences in success rates between our trial and the
ECHO and THRIVE studies may be a reflection of
differences in trial design (open label vs. blinded) or a
consequence of random fluctuations. Visit-by-visit data
(Fig. 1) suggest a similar dynamic of virologic success over
the 96 weeks of treatment between the two groups.
Significant differences in virologic success between
subgroups with equal to or less than 100 000 HIV-1
RNA copies/ml and greater than 200 CD4þ cells/ml
(Table 2) could be related to the higher rate of
discontinuations due to adverse events in the EFV/
FTC/TDF group. In addition, the higher virologic
failure rates observed for RPV/FTC/TDF-treated
participants with baseline HIV-1 RNA greater than
500 000 copies/ml and CD4þ cell count equal to or less
than 200 cells/ml were mainly due to a higher rate of
discontinuation due to lack of efficacy in this group.
However, the efficacy analyses in individuals with high
baseline HIV-1 RNA levels and low CD4þ cell counts
were limited by a small number of participants in those
categories. Compared with the results of the ECHO and
THRIVE trials [6–9], the STaR week 96 data suggest a
more favorable profile for RPV/FTC/TDF for partici-
pants with HIV-1 RNA equal to or less than
100 000 copies/ml (Tables 1 and 2).
Overall rates of resistance development through week 96 in
the STaR study were low (5.3% RPV/FTC/TDF; 1.0%
EFV/FTC/TDF) with infrequent emergent resistance after
week 48 (1.0% RPV/FTC/TDF; 0.3% EFV/FTC/TDF)
[19]. However, a greater proportion of study participants
who met the criteria for resistance analysis developed
resistance in the RPV/FTC/TDF arm (88%) compared
with the EFV/FTC/TDF arm(44%). In this trial, resistance
development was lower compared with the previous phase
3 studies conducted using the components of these two
regimens (8.0% RPV þ FTC/TDF; 3.1% EFV þ FTC/
TDF) [20]. Within the RPV/FTC/TDF arm, resistance
was more frequent in individuals with baseline HIV-1
RNA greater than 100 000 copies/ml than those with
HIV-1 RNA or less than 100 000 copies/ml [10,19].
This study also confirms the overall better safety and
tolerability profile of RPV/FTC/TDF vs. EFV/FTC/
TDF over 96 weeks of treatment, especially in terms of
neuropsychiatric adverse effects and rash. Several sources,
including approved labeling, a systematic review [21], and
ECHO and THRIVE data [22], describe nervous system
and psychiatric disorders as generally developing during
the first days of treatment with EFV and resolving within
2–4 weeks. Data from the current study, however, show
that the majority of TEAEs occurred during the first 48
weeks of treatment [23] and discontinuations due to these
TEAEs were not limited to the earliest weeks of treatment.
This is consistent with the Leutscher et al. study [24], which
found that more than half of EFV-related discontinuations
due to neuropsychiatric adverse events occurred after 12
months of treatment; however, that study was a retro-
spective chart review, which limits comparability with the
current prospective, randomized, open-label trial. Patient-
reported data on treatment satisfaction (HIVTSQ), disease
symptoms (HIV SIQ), and the mental health composite
score (SF-12) also indicate better tolerability of RPV/
FTC/TDF compared with EFV/FTC/TDF.
A decreased eGFR observed in the RPV/FTC/TDF
group is consistent with RPV’s inhibition of the renal
tubular secretion of creatinine in the kidney (Gilead, data
on file, 2010) [25], which has not been associated with the
development of renal failure or chronic kidney disease.
This interpretation is supported by the pattern of the early
decrease in creatinine clearance in the RPV/FTC/TDF
group that occurred at week 4 and then remained stable
thereafter (data not shown). Moreover, proteinuria rates
were low in both treatment arms and no episode of
proximal renal tubulopathy was observed during the trial.
An important limitation of this trial was the open-label
design, which may have contributed to bias in assessment
of outcomes, particularly those related to safety and
tolerability. In addition, the study sample was predomi-
nantly male (93%) and white (67%), which, although a
common characteristic of recent HIV trials, is not
reflective of the global, US, or European HIV-positive
populations [26].
In conclusion, results of this randomized trial indicate that
RPV/FTC/TDF STR is an effective option for first-line
therapy in treatment-naive patients infected with HIV-1,
with better tolerability than EFV/FTC/TDF.
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